Today's top medical abstracts
Rheumatology
Become a Member Today!
Email
Password
Remember me
Forgot your Password?

Invite Code?

Home
General Rheumatology
For Practicing
Rheumatologists
Conferences
Jobs
Newsletters
My Library
Topics in
Rheumatology
        Amyloidosis
        Autoimmune/Heritable
        Basic Science/Genetics
        Bone Metabolism
        Chr Fatigue/Fibromyalgia
        Clinical Pharmacology
        Connective Tissue Dz
        Diagnostics/Radiology
        Economics of Medicine
        Gout and Hyperuricemia
        Infectious Arthritis
        Osteoarthritis
        Other Arthritis
        Pediatric Rheumatology
        Popular Press
        Rheumatoid Arthritis
        Spondylarthropathies
        Systemic Lupus (SLE)
        Vasculitic Syndromes
 
Help
Resource Center
RSS News Feeds
Send Newsletter
to a Friend
 
Sponsor
For Practicing Rheumatologists
Today's Rheumatology News: Joint Symptoms More Common In Breast Cancer Patients
D Scott Cunningham MD, PhD, MDLinx Rheumatology
Today's Rheumatology News: FDA Approves Actemra
D Scott Cunningham MD, PhD, MDLinx Rheumatology
From the Editors: New Clinical-Only Option for MDLinx!
Stephen Smith, MDLinx
  See all
juvenile idiopathic arthritis;longterm outcome Article Summary

Click the title below to leave the MDLinx Network and go to the Journal's Website
Longterm outcome of amyloidosis associated with juvenile idiopathic arthritis
Journal of Rheumatology, 04/18/08
Print     Email This Article     Save in My Library   Free Abstract
Immonen K et al. - The outcome of Juvenile Idiopathic Arthritis (JIA)-associated amyloidosis is poor. However, renal disease regressed in some patients under vigorous treatment.

Methods
  • Aim was to determine the outcome of amyloidosis associated with JIA
  • Patient registers and amyloidosis biopsy files were scrutinized from 1976-2003 to look for amyloidosis in pts under age 19y
  • Medical records were reviewed and pts were interviewed by telephone
  • The causes of any deaths were obtained from death certificates

Results
  • 16/24 pts (67%) had proteinuria, but none had renal insufficiency
  • The 5-y survival rate of the series was 87.5%, and 10-y survival was 75%
  • 10/24 pts (42%) died during a mean f/u of 15.4y
  • The main cause of death was related to JIA in all pts but one
  • Pts treated with prednisolone alone from the diagnosis of amyloidosis onward had a mortality rate higher than those taking DMARDs and/or cytostatics
  • At the end of f/u, 14 pts (58%) were alive, 12 with normal renal function 1 had renal insufficiency, and 1 proteinuria
  • Proteinuria disappeared in 4 pts who were proteinuric at baseline, and their renal function remained normal
  • All the live pts had completed at least the 9 yrs of compulsory education, and 4 had academic degrees
  • Two female pts had delivered healthy children

Read a Different Specialty
Allergy/Immunology
Anesthesiology
Cardiology
Dermatology
Drugs
Emergency Medicine
Endocrinology
ENT
Family Medicine
Gastroenterology
Hematology-Oncology
Infectious Disease
Internal Medicine
Nephrology
Neurology
OB/Gyn
Ophthalmology
Orthopedics
Pediatrics
Psychiatry
Pulmonology
Radiology
Rheumatology
Surgery
Urology
Profession Index
Dentist
Hospital Administrator
Nurse
    Medical Students
Nurse Practitioner
Pharma/Drug Marketer
    Pharmacist
Physician
Physician Assistants
Article Search
Keyword:
Search:
Published within:
Sort By:
Date Relevance
    
About MDLinx  |  Contact  |  Advertise with MDLinx  |  Site Map  |  Privacy Policy  |  Terms of Use  |  Sign Up For Newsletters  |  Recommend this Site

English |  Español |  Français |  Deutsch |  中文 |  Руccкий |  Norsk |  Nederlands |  Português |  Italiano

©1999-2008 MDLinx, Inc.